Saltar al contenido
Merck

B0200000

Baclofen

European Pharmacopoeia (EP) Reference Standard

Sinónimos:

(±)-Baclofen, (±)-β-(Aminomethyl)-4-chlorobenzenepropanoic acid, Lioresal

Iniciar sesión para ver los precios por organización y contrato.

Seleccione un Tamaño

Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C10H12ClNO2
Número CAS:
1134-47-0
Peso molecular:
213.66
NACRES:
NA.24
PubChem Substance ID:
329773100
UNSPSC Code:
41116107
MDL number:
MFCD00055143

Nombre del producto

Baclofen, European Pharmacopoeia (EP) Reference Standard

InChI

1S/C10H12ClNO2/c11-9-3-1-7(2-4-9)8(6-12)5-10(13)14/h1-4,8H,5-6,12H2,(H,13,14)

SMILES string

ClC1=CC=C(C(CN)CC(O)=O)C=C1

InChI key

KPYSYYIEGFHWSV-UHFFFAOYSA-N

grade

pharmaceutical primary standard

API family

baclofen

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

Gene Information

human ... GABBR1(2550), GABBR2(9568)

¿Está buscando productos similares? Visita Guía de comparación de productos

Categorías relacionadas

Application

Baclofen EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

GABAB receptor agonist; skeletal muscle relaxant; antispastic agent.

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Other Notes

Sales restrictions may apply.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

pictograms

Skull and crossbones
GHS06

signalword

Danger

hcodes

H301

Hazard Classifications

Acute Tox. 3 Oral

Clase de almacenamiento

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documentos section.

Si necesita más asistencia, póngase en contacto con Atención al cliente

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

April Erwin et al.
Multiple sclerosis (Houndmills, Basingstoke, England), 17(5), 623-629 (2011-02-02)
The majority of patients with multiple sclerosis (MS) have symptoms of spasticity that increasingly impair function as the disease progresses. With appropriate treatment, however, quality of life can be improved. Oral antispasticity medications are useful in managing mild spasticity but
Amanda McIntyre et al.
The journal of spinal cord medicine, 37(1), 11-18 (2013-10-05)
To review the available evidence on the effectiveness of intrathecal baclofen in the treatment of spasticity in individuals with spinal cord injuries (SCIs) at least 6 months post-injury or diagnosis. A literature search of multiple databases (Pub Med, CINAHL, EMBASE)
Tamis W Pin et al.
Developmental medicine and child neurology, 53(10), 885-895 (2011-06-04)
Studies on the use of intrathecal baclofen (ITB) for ambulant adults with spasticity and/or dystonia of cerebral origin are scarce, and are even more limited for children and adolescents. This systematic review investigates the use of ITB to improve walking
Susan Sangha et al.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 39(10), 2405-2413 (2014-04-15)
Accurate discrimination of environmental cues predicting reward, fear, or safety is important for survival. The prelimbic and infralimbic cortices are implicated in regulating reward-seeking and fear behaviors; however, no studies have examined their roles in discriminating among reward, fear, and
Giovanni Addolorato et al.
Current pharmaceutical design, 16(19), 2113-2117 (2010-05-21)
Preclinical studies show that antagonism of the GABA(B) receptor may represent an effective neuropharmacological approach to treat alcohol dependence. Consistent with preclinical evidence, the majority of the human studies have demonstrated that the prototype GABA(B) receptor antagonist baclofen may represent
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico